Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT05837897 |
| Consolidated Lead Sponsor | Takeda |
| Therapeutic Condition Cohort | Immunology, Rheumatology, and Dermatology |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 408 participants (ESTIMATED) |
| Registered Start Date | 2023-06-16 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| The Second Hospital of Anhui Medical University | Hefei, China | Open Hospital Dossier -> |
| Peking University Third Hospital | Beijing, China | Open Hospital Dossier -> |
| The First Affiliated Hospital Of Fujian Medical University | Fuzhou, China | Open Hospital Dossier -> |
| Lanzhou University Second Hospital | Lanzhou, China | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.